2022-502881-25-00已完成2 期
A Global, Open-label Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Hemophilia B With Inhibitors (PRESent-3)
Apcintex Limited6 个研究点 分布在 4 个国家目标入组 6 人开始时间: 2023年8月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
- 试验地点
- 6
- 主要终点
- Study Endpoint: Treated bleeds (expressed as annualized bleeding rate [ABR]) in the observation period and during the first 24 weeks under SerpinPC
研究概览
简要总结
To evaluate the efficacy and safety of prophylactic SerpinPC administered subcutaneously in subjects with hemophilia B (HemB) with inhibitors
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Open-label
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（18-64 Years, 0-17 Years）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male subjects ≥12 and ≤65 years of age at the time of informed consent
- •Adequate hematologic function, defined as a platelet count of ≥100,000/μL (≥100 × 109/L) and hemoglobin level of ≥10 g/dL (≥100 g/L or ≥ 6.206 mmol/L) at Screening and Pre-dosing visits
- •Adequate hepatic function, defined as a total bilirubin level of ≤1.5 × upper level of normal (ULN, excluding Gilbert syndrome) and aspartate aminotransferase and/or alanine aminotransferase of ≤3 × ULN at Screening and Pre-dosing visits; no clinical signs or known laboratory or radiographic evidence consistent with cirrhosis of the liver
- •Adequate renal function, defined as a serum creatinine level of ≤2.0 × ULN at Screening and Pre-dosing visits
- •Able to use a diary to document bleeding events and medication usage (caregiver assistance allowed for adolescents)
- •Sexually active subjects with a partner who could become pregnant should agree to use effective contraception for the duration of the study Effective contraceptive measures include condom with or without spermicide, a combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods), vasectomy, partner using stable contraceptive measures (combined [estrogen and progestogen-containing] hormonal contraception or progestogen-only hormonal contraception initiated 2 or more menstrual cycles prior to screening, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal ligation), and/or sexual abstinence
- •Capable of providing written informed consent (adolescent assent and parental/guardian/legal representative consent when appropriate) for participation and having the opportunity to discuss the study with the Investigator or delegate
- •Historically documented HemB (defined as factor IX ≤0.05 IU/mL [≤5%])
- •Subjects who are currently in a prophylaxis program must be willing to stop prophylaxis (including episodic prophylaxis for sporting events) before the first dose of SerpinPC
- •Historical or ongoing factor IX inhibitor requiring current treatment with bypass agents based on medical records or laboratory reports
- •Documented ABR of ≥6 in the 12 months before screening (subjects not on prophylaxis regimen) or documented ABR of ≥2 for subjects on prophylaxis regimen
- •At least 12 weeks of prospective documentation of bleeding episodes in the AP-0105 non-interventional study before SerpinPC dosing, or willing to complete a 12-week observational period (at minimum) in AP-0103
- •No bleeding in the 7 days before Baseline (the prospective observation period can be extended if there is an ongoing active bleed)
- •D-dimer of ≤750 μg/L; in cases where there is a resolving bleed, the exclusion threshold is ≤1750 mg/L at Screening and Pre-dosing visits
排除标准
- •Known severe thrombophilia (defined as antithrombin deficiency and/or protein S deficiency and/or protein C deficiency)
- •Any major medical, psychological, or psychiatric condition that could cause the subject to be unsuitable for the study or could interfere with the interpretation of the study results
- •History of or other evidence of recent alcohol or drug abuse as determined by the Investigator (in the 12 months before screening)
- •Known HIV infection with CD4 count (or T-cell count) of <200 cells/μL within 24 weeks before Screening and Pre-dosing visits. Patients with HIV infection who have CD4 > 200 and meet all other criteria are eligible
- •Current or planned treatment with anticoagulant or antiplatelet drugs
- •Is planning to donate/bank sperm during SerpinPC treatment AND within 30 days of last dose of SerpinPC
- •Any other significant conditions or comorbidities that, in the opinion of the Investigator, would make the subject unsuitable for enrollment, or could interfere with participation in, or completion of the study
- •Patient with previous factor IX inhibitor who responded to immune tolerance induction and remains on prophylactic factor concentrate
- •Previous deep vein thrombosis (excluding line-associated thrombosis), pulmonary embolism, myocardial infarction, or stroke
- •History of intolerance to SC injections
- •Uncontrolled hypertension (systolic blood pressure >160 mm Hg; diastolic blood pressure >100 mm Hg)
- •Weight >150 kg OR body mass index >40 kg/m2
- •Has active cancer and/or requires therapy for cancer, except for basal cell carcinoma
- •Participation in another interventional clinical trial (except for AP-0105) during the 30 days before screening
- •Ongoing, or planned treatment with gene therapy for HemB
结局指标
主要结局
Study Endpoint: Treated bleeds (expressed as annualized bleeding rate [ABR]) in the observation period and during the first 24 weeks under SerpinPC
Study Endpoint: Treated bleeds (expressed as annualized bleeding rate [ABR]) in the observation period and during the first 24 weeks under SerpinPC
次要结局
- • Treated bleeds (expressed as ABR) other than those defined by the primary endpoint (eg, during the first 48 weeks)
- • Treated spontaneous bleeds (expressed as ABR)
- • Treated spontaneous joint bleeds (expressed as ABR)
- • All bleeds requiring treatment (expressed as ABR; ie, all bleeds that would ordinarily be treated with factor concentrate/bypass agent if therapy were available)
- • Total coagulation factor and/or bypass product consumption during SerpinPC treatment
- • PK concentrations of SerpinPC throughout the study
- • Haemophilia Quality-of-Life Questionnaire for Adults (Haem-A-QoL) Physical Health scale in subjects aged 17 to ≤65 years
研究者
Chief Medical Officer
Scientific
Apcintex Limited
研究点 (6)
Loading locations...
相似试验
招募中
3 期
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents2024-512837-34-00Teva Branded Pharmaceutical Products R&D LLC249
招募中
1 期
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07275736Juventas Cell Therapy Ltd.18
尚未招募
1 期
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07265206Juventas Cell Therapy Ltd.15
招募中
3 期
Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors2023-506832-33-00Novo Nordisk A/S43
招募中
2 期
A clinical study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SB-007 in Subjects with Stargardt Disease.2024-519535-42-00Splicebio S.L.10